Nestlé

GLP-1 weight-loss drugs fuel biotech and food sector growth

Semaglutid-based therapies drive expansion in pharmaceuticals and food innovation as companies target the $100 billion obesity treatment market.

Markets Desk · 19 Aug 2026

EquitiesArticle

JPMorgan Maintains Neutral Rating on Nestlé, Citing Russia Operations

US investment bank JPMorgan keeps its neutral stance and a price target of 90 Swiss francs on food giant Nestlé.

Markets Desk · 18 Aug 2026

EquitiesArticle

Nestlé faces potential loss of control over Russian operations

Russian logistics firm KS Logistika seeks to take over Nestlé’s local business amid legal and regulatory pressures. Swiss conglomerate confirms talks but denies outright expropriation.

Markets Desk · 18 Aug 2026